These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 29187901)
1. Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. Jiang T; Li X; Wang J; Su C; Han W; Zhao C; Wu F; Gao G; Li W; Chen X; Li J; Zhou F; Zhao J; Cai W; Zhang H; Du B; Zhang J; Ren S; Zhou C; Yu H; Hirsch FR Theranostics; 2017; 7(19):4753-4762. PubMed ID: 29187901 [No Abstract] [Full Text] [Related]
2. Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer. Shi M; Yuan H; Ji J; Zhang S; Li Q; Chen Y; Gong X; Zhu Z; Zhang J Ther Adv Med Oncol; 2022; 14():17588359211070643. PubMed ID: 35096147 [TBL] [Abstract][Full Text] [Related]
3. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy. Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290 [TBL] [Abstract][Full Text] [Related]
4. Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer. Macedo-Pérez EO; Morales-Oyarvide V; Mendoza-García VO; Dorantes-Gallareta Y; Flores-Estrada D; Arrieta O Cancer Chemother Pharmacol; 2014 Oct; 74(4):681-90. PubMed ID: 25059320 [TBL] [Abstract][Full Text] [Related]
5. Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy. Najjar F; Al-Massarani G; Banat I; Alammar M Int J Biol Markers; 2015 Nov; 30(4):e374-81. PubMed ID: 26109363 [TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China. Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285 [TBL] [Abstract][Full Text] [Related]
7. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L; Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168 [TBL] [Abstract][Full Text] [Related]
8. Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma. Jiang T; Jiang L; Dong X; Gu K; Pan Y; Shi Q; Zhang G; Wang H; Zhang X; Yang N; Li Y; Xiong J; Yi T; Peng M; Song Y; Fan Y; Cui J; Chen G; Tan W; Zang A; Guo Q; Zhao G; Wang Z; He J; Yao W; Wu X; Chen K; Hu X; Hu C; Yue L; Jiang D; Wang G; Liu J; Yu G; Li J; Zhang H; Wu L; Fang L; Liang D; Zhao Y; Zhao W; Xie W; Ren S; Zhou C Theranostics; 2021; 11(1):257-267. PubMed ID: 33391473 [No Abstract] [Full Text] [Related]
9. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Ren S; Zhou S; Zhang L; Xu J; Lv M; Zhang J; Zhou C; Zhang J Cancer Invest; 2010 Dec; 28(10):1078-83. PubMed ID: 20504223 [TBL] [Abstract][Full Text] [Related]
10. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance. Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170 [TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy. Najjar F; Alammar M; Bachour M; Almalla N; Altahan M; Alali A; Al-Massarani G J Cancer Res Clin Oncol; 2015 Jan; 141(1):119-25. PubMed ID: 25037116 [TBL] [Abstract][Full Text] [Related]
12. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Booton R; Lorigan P; Anderson H; Baka S; Ashcroft L; Nicolson M; O'Brien M; Dunlop D; O'Byrne K; Laurence V; Snee M; Dark G; Thatcher N Ann Oncol; 2006 Jul; 17(7):1111-9. PubMed ID: 16603599 [TBL] [Abstract][Full Text] [Related]
13. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561 [TBL] [Abstract][Full Text] [Related]
14. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Zhuo M; Guan Y; Yang X; Hong L; Wang Y; Li Z; Chen R; Abbas HA; Chang L; Gong Y; Wu N; Zhong J; Chen W; Chen H; Dong Z; Zhu X; Li J; Wang Y; An T; Wu M; Wang Z; Wang J; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Lee JJ; Heymach JV; Wistuba II; Kalhor N; Yang L; Yi X; Futreal PA; Glisson BS; Xia X; Zhang J; Zhao J Clin Cancer Res; 2020 Feb; 26(4):892-901. PubMed ID: 31694833 [TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy. Giroux Leprieur E; Antoine M; Vieira T; Duruisseaux M; Poulot V; Rabbe N; Belmont L; Gounant V; Lavolé A; Milleron B; Lacave R; Cadranel J; Wislez M Lung Cancer; 2013 Feb; 79(2):167-72. PubMed ID: 23153658 [TBL] [Abstract][Full Text] [Related]
16. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients. Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272 [TBL] [Abstract][Full Text] [Related]
17. Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer. Luo J; Leaw SJ; Xu Y; Zheng D Med Oncol; 2011 Dec; 28(4):1418-24. PubMed ID: 20661668 [TBL] [Abstract][Full Text] [Related]
18. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb. Fischer JR; Griesinger F; Fink T; Salm T; Marseille A; Wolf M Lung Cancer; 2012 Mar; 75(3):348-52. PubMed ID: 21908069 [TBL] [Abstract][Full Text] [Related]
19. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation. Hirano S; Naka G; Takeda Y; Iikura M; Hayama N; Yanagisawa A; Amano H; Nakamura M; Nakamura S; Tabeta H; Sugiyama H Chin Clin Oncol; 2016 Dec; 5(6):77. PubMed ID: 28061541 [TBL] [Abstract][Full Text] [Related]
20. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. Herbst RS; Giaccone G; de Marinis F; Reinmuth N; Vergnenegre A; Barrios CH; Morise M; Felip E; Andric Z; Geater S; Özgüroğlu M; Zou W; Sandler A; Enquist I; Komatsubara K; Deng Y; Kuriki H; Wen X; McCleland M; Mocci S; Jassem J; Spigel DR N Engl J Med; 2020 Oct; 383(14):1328-1339. PubMed ID: 32997907 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]